Core Insights - The 2025 Academic Annual Meeting of the Chinese Association of Integrative Medicine for Dermatology and Venereology was held in Shanghai, focusing on advancements in dermatology and integrative therapies [1] - A new drug for atopic dermatitis (AD), Zeli Mei, was highlighted as a significant breakthrough in the field, showcasing a unique mechanism of action [1] Group 1: Drug Characteristics - Zeli Mei has five key characteristics: rapid onset of action, significant efficacy, outstanding therapeutic effects comparable to systemic treatments, durable effects with low relapse rates, and excellent safety profile [2] - Clinical data shows that Zeli Mei improves itching symptoms within the first day and significantly enhances skin lesions within seven days [2] - The EASI75 response rate after eight weeks of treatment is 54.4%, with even higher rates in children aged 2 to 17 years, reaching 69.2% and 83.9% in the 7 to 11 age group [2] Group 2: Expert Opinions - Experts at the conference responded positively to the presentation, noting the significant improvement in patients' itching and scratching behaviors after using Zeli Mei [3] - The drug offers a new option for clinicians, especially for children, due to its efficacy and safety, providing an alternative to traditional non-steroidal medications [3] - Zeli Mei, designed specifically for AD and based on the innovative AhR modulation mechanism, presents substantial therapeutic potential [3]